1ISG-008 Economic impact of the use of biosimilar infliximab in a second-level hospital

BACKGROUND: The high price of biological drugs has become progressively unsustainable to the national health system. The development of biosimilar drugs might represent an option in reducing healthcare costs. PURPOSE: To analyse the economic impact of incorporating biosimilar infliximab (BI) in a se...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Hosp Pharm
Main Authors: Mora, AB Morillo, Rosa, V Gonzalez, Torres, MI Sierra
Format: Artigo
Language:Inglês
Published: BMJ Group 2018
Subjects:
Section 1: Introductory statements and governance
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535246/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items